Global X NASDAQ 100 Covered Call ETF vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.63 (market cap $8.54B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is the larger of the two by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| QYLD | RDY | |
|---|---|---|
Market Cap | $8.54B | $10.61B |
Volume | 2,727,578 | 3,738,869 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.69 | $15.38 |
52-Week Low | $16.70 | $11.38 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $10.51B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains its covered call strategy on the Nasdaq 100, generating consistent monthly dividends of $0.18 per share. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, while RSI levels above 75 suggest overbought conditions. Recent news highlights concerns about principal erosion despite the attractive yield.
The outlook remains cautious as QYLD's high yield comes with capped upside potential during market rallies. While providing reliable monthly income, the strategy sacrifices long-term capital appreciation. Key risks include declining option premiums and tax treatment uncertainties that could impact total returns for income-focused investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →